Genprex Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$16.2MTTM through 30 Jun 2026
Free Cash Flow -$15.6MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-98.8%ROE
-92.7%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio6.77x
Net Debt-$18Mnet cash position
Cash & Equivalents$15.2M
Quality Metrics
Altman Z-Score-16.00
Piotroski F-Score3 / 9
Earnings-Beat Rate66.7%
Multi-Year Trend
RevenueFY2024: $0
Diluted EPSFY2025: $-17.40
Dividend
No dividend
Capital Allocation
R&D Spend$9.8M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Oncology | $0 | View detailsExpects to complete enrollment of the first 19 patients for interim analysis in the Phase 2a expansion portion of the Acclaim-1 study in the first half of 2026, with interim analysis expected in the second half of 2026. | |
| Diabetes | $0 | View detailsFollowing a positive FDA meeting in February 2026, the company plans to continue preclinical animal studies to finalize the design and initiate future toxicology studies. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.